Skip to main content

Table 2 Variables associated with Hb reduction > 3 g/dl

From: Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy

  Univariate analysis Multivariate analysis
Characteristics Odds ratio [95% CI] Pvalue Odds ratio [95% CI] Pvalue
Week 4     
  EPO rs1617640 (GG vs. TT/TG) 1.66 [0.92 – 2.94] 0.088 2.17 [1.09 – 4.30] 0.025
  ITPA rs1127354 (additive) 0.35 [0.15 – 0.71] 0.007 0.32 [0.13 – 0.70] 0.007
  Age (years) 0.97 [0.95 – 0.99] 0.0085 0.97 [0.95 – 1.00] 0.02
  Sex (female vs. male) 0.75 [0.44 – 1.26] 0.285 1.64 [0.88 – 3.07] 0.12
  Baseline Hb (g/dl) 2.24 [1.76 – 2.92] < 0.001 2.50 [1.91 – 3.34] < 0.001
  RBV starting dose* 2.49 [1.03 – 7.34] 0.011 2.50 [1.03 – 7.34] 0.036
Week 12
  EPO rs1617640 (GG vs. TT/TG) 1.57 [0.92 – 2.70] 0.064 1.97 [1.07 – 3.66] 0.029
  ITPA rs1127354 (additive) 0.60 [0.35 – 1.01] 0.058 0.58 [0.32 – 1.03] 0.067
  Age (years) 0.97 [0.95 – 0.99] 0.002 0.97 [0.95 – 0.99] 0.004
  Sex (female vs. male) 0.86 [0.55 – 1.33] 0.49 1.75 [1.04 – 2.99] 0.084
  Baseline Hb (g/dl) 1.90 [1.55 – 2.35] < 0.001 2.08 [1.67 – 2.64] < 0.001
  RBV starting dose* 2.09 [1.20 – 3.79] 0.011 2.18 [1.17 – 4.20] 0.016
  1. Abbreviations: EPO erythropoietin, ITPA inosine triphosphatase, RBV ribavirin, CI confidence interval. *RBV starting dose is coded as an ordered categorical variable with levels of 800, 1000, 1200, and 1400 mg with linear increments.